⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025Open Access

Supplementary Figure S2 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

Chan Xie Xingrong Zheng Songmin He Wenxiong Xu Wenbo Zhu Guangmei Yan Liang Peng

View Full Paper

Ask AI

Bookmark

Share

Key Points

Testing revealed viral titers in patient serum samples after treatment with oncolytic virus therapy.
Samples showed positive viral RNA copies, indicating the presence of the oncolytic virus in the serum.
The study focuses on advanced hepatocellular carcinoma, assessing the combination therapy's effectiveness.
Findings may enhance understanding of oncolytic virus therapies combined with immunotherapy for liver cancer.

Implication

Clinical evaluation of M1-c6v1 oncolytic virus with camrelizumab and apatinib shows viral titer results in hepatocellular carcinoma.

Abstract

Supplementary Figure 2. Viral titer testing (CCID50/mL) from samples with positive viral RNA copies in serum.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcb6f https://doi.org/10.1158/1078-0432.30363214

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
2Supplementary Figure S1 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
3Supplementary Figure S5 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
4Data from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
5Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.2025 · 12 citations

More related papers

Supplementary Figure 1 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus2024
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial2024
Supplementary Figure S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study2024